Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Gossamer Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Gossamer Bio's regulatory disclosures and financial reporting.
Gossamer Bio, Inc. (GOSS) – Form 4 filing dated 06/26/2025
Non-employee director Skye Drynan received an option grant for 115,000 shares of common stock with an exercise price of $1.36 per share on 06/25/2025. The award was made under the company’s Non-Employee Director Compensation Program.
The option vests 100 % on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued board service. The director now beneficially owns 115,000 derivative securities; no common shares were reported as acquired or sold. Ownership is listed as direct.
No cash transactions, open-market purchases, or sales were disclosed. The filing represents a routine equity incentive and does not indicate any change in the company’s operational outlook or financial condition.
Form 8-K Overview: On 25 June 2025 Gossamer Bio (Nasdaq: GOSS) disclosed the voting results of its 2025 Annual Meeting and the adoption of an Amended & Restated 2019 Incentive Award Plan.
Board Elections: Class I directors Thomas Daniel, Sandra Milligan and Steven Nathan were re-elected for terms expiring in 2028. Support ranged from 80%–88% of votes cast, with 47.1 million broker non-votes recorded.
Auditor Ratification: Ernst & Young LLP was ratified as independent registered public accounting firm for fiscal 2025 by 176.5 million votes for versus 0.1 million against, indicating near-unanimous confidence.
Say-on-Pay: Compensation of named executive officers received strong advisory backing—125.4 million for (≈96%) and 3.8 million against.
Equity Incentive Plan: The Amended & Restated 2019 Incentive Award Plan passed with 87.8 million for and 41.5 million against (≈67.7% approval, excluding broker non-votes). The comparatively higher dissent signals some shareholder concern over potential dilution or pay practices, though the proposal ultimately carried.
Materiality: No financial performance metrics, strategic transactions, or guidance updates were included. The filing is primarily governance-related; its impact centers on confirming board stability, auditor continuity and refreshed equity compensation capacity.